Novel synthetic analogues of avian β-defensin-12: the role of charge, hydrophobicity, and disulfide bridges in biological functions by unknown
RESEARCH ARTICLE Open Access
Novel synthetic analogues of avian
β-defensin-12: the role of charge,
hydrophobicity, and disulfide bridges
in biological functions
Ming Yang1, Chunye Zhang1, Michael Z. Zhang2,3 and Shuping Zhang1,3*
Abstract
Background: Avian β-defensins (AvBD) possess broad-spectrum antimicrobial, LPS neutralizing and chemotactic
properties. AvBD-12 is a chemoattractant for avian immune cells and mammalian dendritic cells (JAWSII) — a unique
feature that is relevant to the applications of AvBDs as chemotherapeutic agents in mammalian hosts. To identify the
structural components essential to various biological functions, we have designed and evaluated seven AvBD analogues.
Results: In the first group of analogues, the three conserved disulfide bridges were eliminated by replacing cysteines with
alanine and serine residues, peptide hydrophobicity and charge were increased by changing negatively charged amino
acid residues to hydrophobic (AvBD-12A1) or positively charged residues (AvBD-12A2 and AvBD-12A3). All three
analogues in this group showed improved antimicrobial activity, though AvBD-12A3, with a net positive charge of +9,
hydrophobicity of 40% and a predicted CCR2 binding domain, was the most potent antimicrobial peptide. AvBD-12A3
also retained more than 50% of wild type chemotactic activity. In the second group of analogues (AvBD-12A4 to AvBD-
12A6), one to three disulfide bridges were removed via substitution of cysteines with isosteric amino acids. Their
antimicrobial activity was compromised and chemotactic activity abolished. The third type of analogue was a
hybrid that had the backbone of AvBD-12 and positively charged amino acid residues AvBD-6. The antimicrobial and
chemotactic activities of the hybrid resembled that of AvBD-6 and AvBD-12, respectively.
Conclusions: While the net positive charge and charge distribution have a dominating effect on the antimicrobial
potency of AvBDs, the three conserved disulfide bridges are essential to the chemotactic property and the maximum
antimicrobial activity. Analogue AvBD-12A3 with a high net positive charge, a moderate degree of hydrophobicity and
a CCR2-binding domain can serve as a template for the design of novel antimicrobial peptides with chemotactic
property and salt resistance.
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Background
Rapid emergence of antimicrobial resistance poses a
major global threat to public health and the economy
[1, 2]. Excessive use and misuse of antibiotics in
medicine and food production contribute to the rise
of drug resistant pathogens [3, 4]. Control and pre-
vention of antibiotic resistance call for holistic
strategies including judicious use of antimicrobials, ef-
fective diagnostic tools, and novel therapeutic agents
that are less likely to trigger resistance [5].
Beta-defensins are small, cationic, antimicrobial pep-
tides found in different living organisms [6–9]. These
endogenous peptides constitute the first line of innate
defense against pathogenic bacteria, fungi, and viruses
[10, 11]. Beta-defensins possess various biological prop-
erties, including broad-spectrum microbicidal activity,
neutralization of LPS, activation of macrophages and
dendritic cells, chemoattraction of dendritic cells,
monocytes, and T-lymphocytes to the site of infection
[7, 10, 12]. The microbicidal activity of defensins is
achieved mainly through initial electrostatic attraction
between positively charged amino acid residues of the
peptides and negatively charged microbial surface
components and subsequent microbial membrane
damage which is followed by interacting with intracel-
lular targets [13–15]. The chemotactic function of β-
defensins is mediated by CC-chemokine receptors,
such as CCR2 and CCR6 [16–18]. These natural anti-
microbial peptides with complex mechanisms of
action represent potentially a novel class of antimicro-
bials [13, 19]. However, several challenges must be
addressed in order to develop β-defensins for thera-
peutic use which include retaining the biological ac-
tivities under physiological conditions and the ease of
production and purification of recombinant or syn-
thetic peptides [20, 21].
Most defensin peptides characterized to date have a
net positive charge, ranging from +2 to +9, and
hydrophobicity of approximately 30-50% [15]. It has
been reported that the three conserved disulfide brid-
ges are required for the chemotactic function, but not
the antimicrobial activity [17, 22–25]. Data from our
laboratory showed that reduced (or linear form)
AvBDs are fully active against bacterial pathogens
whereas AvBDs without correctly folded disulfide
bridges are not [21, 26]. To further understand the
structural and functional characteristics of AvBDs,
seven analogues were designed by replacing the negatively
charged residues (D and E) and/or cysteines (C) with ei-
ther positively charged residues (H, K, and R), hydropho-
bic residues (A, I, L, and V) or isosteric amino acids
(Abu). The antimicrobial and chemotactic activities and
salt-resistance of the analogues as well as their wild type
parent peptides have been evaluated.
Methods
Design and synthesis of peptides
The three dimensional structures of AvBDs were pre-
dicted by using the I-TASSER program (http://zhan
glab.ccmb.med.umich.edu/I-TASSER). The distribution
of positively charged amino acids were evaluated using
PyMOL (https://www.pymol.org/). Group 1 analogues,
including AvBD-12A1, A2 and A3 were linear pep-
tides, in which the six cysteines (C1C2C3C4C5C6 or
C5C12C17C27C34C35) were replaced with structur-
ally similar amino acid residues (alanine and serine)
as follows: AvBD-12A1: A5A12A17A27A34A35, AvBD-
12A2: S5S12S17A27A34A35, and AvBD-12A3: A5A12A
17S27S34S35. Additional modifications were introduced
to these analogues to alter peptide hydrophobicity and
charge. In AvBD-12A1, the four negatively charged
amino acid residues (D3D8E21E29) were replaced
with one polar and three hydrophobic amino acid res-
idues (H3V8L21I29). In AvBD-12A2 and AvBD-12A3,
D3D8E21E29 were substituted with positively charged
residues R3K8K21R29. Group 2 analogues, including
AvBD-12A4, AvBD-12A5 and AvBD-12A6 had re-
duced number of disulfide bridges without any add-
itional modifications. To remove disulfide bridges, the
cysteine residues (C1C2C3C4C5C6 or C5C12C17C2
7C34C35) of AvBD-12 were replaced with isosteric α-
aminobutyric acids (Abu, U) to create AvBD-12A4
(U5C12C17C27U34C35), A5 (U5U12C17U27U34C35),
and A6 (U5U12U17U27U34U35). Group 3 included a
single hybrid peptide, namely AvBD-12/6. This analogue
was designed using the backbone of AvBD-12, in which the
negatively charged amino acid residues (D3D8E21E29) of
AvBD-12 were replaced with amino acids (H3Q8Y21S29)
of AvBD-6 at the corresponding positions. The hydrophobi-
city and charge of AvBD analogues at neutral pH were cal-
culated using Peptide 2.0 (http://peptide2.com) and Peptide
property calculator (PepCalc.com), respectively.
All peptides were custom synthesized using the standard
solid phase 9-fluorenylmethoxycarbonyl (Fmoc) method
and purified by reverse phase high performance liquid
chromatography (RP-HPLC) (Lifetein, Hillsborough, NJ).
The analogues AvBD-12A4, −A5, AvBD-12/6, AvBD-6
and AvBD-12 with varying numbers of cysteine residues
were subjected to oxidative folding as described previously
[17]. Electrospray ionization mass spectrometry (ESI-MS)
was performed to confirm the correct formation of disul-
fide bridges between Cys1-Cys5, Cys2-Cys4 and Cys3-Cys6.
The purity of the synthetic AvBD analogues was over
98.5% as verified by liquid chromatography-mass spec-
trometry (LC-MS) (Lifetein, Hillsborough, NJ).
Antimicrobial activity of AvBD analogues
Escherichia coli (ATCC 25922), Pseudomonas aeruginosa
(ATCC 27853), Salmonella enteric serovar Typhimurium
Yang et al. BMC Microbiology  (2017) 17:43 Page 2 of 14
(ATCC 14028) and Staphylococcus aureus (ATCC
29213) were used to assess the antimicrobial activity of
AvBD analogues. All bacterial strains were grown on
Luria-Bertani (LB) agar plates or Trypticase Soy Agar
with 5% Sheep Blood (TSA, Thermo Fisher Scientific)
plates at 37 °C. Antimicrobial activity was determined by
a colony counting assay [21, 26]. In brief, bacteria were
resuspended in 100-fold diluted Mueller Hinton II broth
with 5 mM NaCl (minimal growth medium) to obtain a
final bacterial concentration of 2 × 105 CFU/ml. Twenty-
five microliters of bacterial suspension and 25 μl of
AvBD analogue solution were mixed in the wells of a
96-well polypropylene microtiter plate (Nunc™, Thermo
Fisher Scientific). The final peptide concentrations were
2, 4, 8, 16, 32, 64 and 128 μg/ml. The minimal growth
medium without AvBD peptide was included as a nega-
tive control. The bacterial-peptide mixtures were incu-
bated at 37 °C for 2 h, ten-fold serially diluted and
plated on LB agar plates. The numbers of bacteria col-
onies were enumerated after 16 h of incubation at 37 °C.
Antimicrobial activity was expressed as percent of killing
using the following formula: (CFUcontrol - CFUtreated) /
CFUcontrol × 100%. To assess the resistance of AvBD ana-
logues to sodium chloride (NaCl), antimicrobial assays
were carried out in the presence of 5 mM, 50 mM,
100 mM or 150 mM NaCl. All assays were performed in
triplicate.
Minimum inhibitory concentrations of AvBD analogues
The minimum inhibitory concentrations (MIC) of AvBDs
were determined according to the guidelines of the Clinical
and Laboratory Standards Institute (CLSI) [27, 28]. The
Muller Hinton II broth used in standard MIC assays con-
tained 20–25 mg/L of calcium and 10–12.5 mg/L of mag-
nesium. Modified MICs of AvBDs were also determined
under a low-salt and low-nutrient condition by using 100×
diluted Muller Hinton II broth containing 0.2 mg/L of cal-
cium, 0.1 mg/L magnesium and 5 mM (292 mg/L) NaCl.
MIC obtained under the low-salt and low-nutrient condi-
tion was referred to as MIC-ls. AvBD peptides were two-
fold serially diluted (2 to 256 μg/ml) in a 96-well microtiter
plate. An equal volume (μl) of bacterial suspension was
added to each well of the plate. The final bacterial concen-
tration in the wells was 5 × 105 CFU/ml. The plate was in-
cubated at 37 °C for 24 h and the lowest concentration that
completely prevented visible bacteria growth was recorded.
To complement MIC-ls assays, the minimum bactericidal
concentrations (MBC) were evaluated by sub-culturing the
contents of the first two clear wells obtained in the MIC-ls
assay onto LB agar plates. All assays were conducted in
triplicate. The lowest peptide concentration inhibiting more
than 99% of bacterial growth was defined as MBC-ls. AvBD
analogues were regarded as bactericidal if the MBC was no
more than four times the MIC [29].
Cell cytotoxicity assay
Chicken macrophage cell lines MQ-NCSU and HD11
were maintained in RPMI-1640 media supplemented
with 10% fetal bovine serum (FBS), 2% chicken serum,
100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-
Aldrich) at 37 °C in humidified air with 5% CO2. CHO-
K1 cells were cultured in the same media without 2%
chicken serum. For CCR2-transfected CHO-K1 cells, the
medium was supplemented with 500 μg/ml G418 was
added (Sigma-Aldrich) [26]. Murine immature dendritic
cell line JAWSII (ATCC CRL-11904™) was cultured in
Alpha minimum essential medium containing 4 mM L-
glutamine, 1 mM sodium pyruvate, 5 ng/ml murine
Granulocyte macrophage colony-stimulating factor
(GM-CSF), 20% FBS, 100 U/ml penicillin and 100 μg/ml
streptomycin at 37 °C in humidified air with 5% CO2.
The cell cytotoxicity was determined using the MTT
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide metabolic activity assay according to the manu-
facturer’s instruction (Thermo Fisher Scientific). Briefly,
cells (5 × 103 cells/well) were seeded in 96-well tissue
culture plates, incubated overnight and treated with
AvBDs at concentrations of 4, 16, 64 and 256 μg/ml for
4, 12, 24 and 48 h at 37 °C. After treatment, 20 μl of
12 mM MTT solution was added to each well. The
plate was incubated for 4 h and read at 540 nm.
Viability was expressed as percentage of viable cells
relative to the untreated control. The experiments
were performed in triplicate.
Chemotaxis assay
Migration of JAWSII and CCR2-CHO-K1 cells in re-
sponse to AvBD-12 analogues was determined using a 48-
well microchemotaxis chamber technique as previously
described [30]. Chemotaxis buffer (Minimum Essential
Medium containing 0.1% BSA, 100U/ml penicillin, and
100 μg/ml streptomycin) and bacterial peptide N-
Formyl-methionyl-leucyl-phenylalanine (fMLF, Sigma-
Aldrich) were included as negative and positive
controls, respectively. The results were presented as
chemotactic index (C.I.). C.I. = number of migrated cells
induced by AvBDs / number of migrated cells induced by
chemotactic buffer. The assay was repeated five times.
Scanning electron microscopy (SEM)
SEM was performed according to the procedure de-
scribed by Cobo et al. [31]. S. Typhimurium was cul-
tured in Mueller-Hinton (MH) broth to mid-log phase
and harvested by centrifugation at 5000 g for 10 min.
Cell pellets were washed twice with 10 mM PBS and re-
suspended at a final number of 108 CFU. The cell sus-
pension was incubated with 1 ×MIC-ls of AvBD-12A3,
AvBD-12/6, wild-type AvBD-6 and AvBD-12 at 37 °C for
30 min. Bacterial pellets were fixed in 500 ml of 2.5% (v/v)
Yang et al. BMC Microbiology  (2017) 17:43 Page 3 of 14
glutaraldehyde in 0.2 M cacodylate buffer at 4 °C over-
night, washed twice with 0.2 M cacodylate buffer and
dehydrated through ethanol gradient (30%, 50%, 70%,
90%, 100% and again 100%) for 15 min in each gradient.
The samples were transferred into a mixture (1:1, v/v) of
ethanol and tertiary butanol and then pure tertiary buta-
nol for 20 min each. After gold coating, the specimens
were observed using a scanning electron microscope
(Hitachi S-4700, Japan).
Statistical analysis
Data were presented as the means ± standard deviation
(SD). Differences between groups were analyzed using the
one-way analysis of variance (ANOVA) followed by
Duncan’s test for multiple comparisons using software
SPSS version 19.0 (IBM Corp., Armonk, NY). Differences
at p < 0.05 level were considered statistically significant, and
at p < 0.01 level were considered extremely significant.
Results
Structural characteristics of AvBD-6 and AvBD-12 and
their analogues
Substitutions of C1C2C3C4C5C6 (or C5C12C17C27C34C35)
by A5A12A17A27A34A35 (AvBD-12A1) not only elimi-
nated the three disulfide bridges, but also elevated the
hydrophobicity from 33% (AvBD-12) to 47%. Additional
H3V8L21I29 for D3D8E21E29 substitutions further in-
creased the hydrophobicity to 53% and the net positive
charge from +1 (AvBD-12) to +5 (AvBD-12A1). Changes
from C1C2C3C4C5C6 to S5S12S17A27A34A35 (AvBD-
12A2) or to A5A12A17S27S34S35 (AvBD-12A3) and
changes from D3D8E21E29 to R3K8K21R29 (AvBD-12A2
and A3) eliminated all three disulfide bridges and increased
the peptide hydrophobicity from 33% to 40% and the net
positive charge from +1 to +9. AvBD-12A4, A5, and A6 re-
spectively lost disulfide bridge(s) C1–5; C1–5 and C2–4; C1–5,
C2–4, and C3–6. C to U changes did not affect the peptide
hydrophobicity and charge. The hybrid AvBD-12/6 with
the backbone of AvBD-12 and the positively charged amino
acids (H3Q8Y21S29) of AvBD-6 retained parent peptides’
hydrophobicity (33%) and an intermediate charge (+5),
compared to AvBD-6 (+7) and AvBD-12 (+1). The se-
quence, charge, hydrophobicity and number of disulfide
bridges of analogues and wild-type AvBD-12 and AvBD-6
were listed in Table 1.
Superimposition of the predicted three dimensional
structures of AvBD-12 and the structure of human
β-defensin 6 (hBD6) revealed a similar N-terminal α-
helix and an adjacent β2-β3 loop, in addition to the con-
served internal β-sheet domains (Fig. 1a). The α-helix
and β2-β3 loop have been identified by NMR spectros-
copy as a contiguous binding surface for human CCR2
[32]. A comparison of the predicted three dimensional
structures of AvBD-6 and AvBD-12 showed only the
β2-β3 loop in AvBD-6. AvBD-6 had an N-terminal coil
turn instead of an α-helix. Peptide charge distribution
analysis indicated that positively charged amino acid res-
idues (H4R7R10R38R40) in the N- and C-termini of
AvBD-6 formed a cluster whereas positively charged res-
idues (H7R9K36) of AvBD-12 were separated by nega-
tively charged residues (Fig. 1d). The N-terminal α-helix
and the β2-β3 loop were also seen in the predicted
structures of AvBD-12A2 and AvBD-12A3. However, dif-
ferences in the β2-β3 loop between AvBD-12A2 and A3
were identified (Fig. 2a). In AvBD-12A2, the -C = O
group in the main chain of F28 formed a hydrogen bond
with the -NH group in the side chain of R29, resulting
in the fold-back of R29 sidechain (Fig. 2b). In AvBD-
12A3, there was no hydrogen bond formation between
R29 and F28. Instead, there are C-H/O interactions
between the -CH groups in the aromatic π ring of
F28 and the -C = O group of F28 as well as the -CH
group in the side chain of S27, similar to what was
reported previously [33]. Consequently, the side chain
of R29 protruded towards the surface of the peptide
and the aromatic ring of F28 in AvBD-12A3 turned
in parallel with R29 side chain (Fig. 2c).
Antimicrobial activity
Group 1 analogues with increased net positive charge
and hydrophobicity were significantly more effective
(p < 0.05) than the parent peptide AvBD-12 in killing
E. coli, S. Typhimurium, P. aeruginosa, and S. aureus
(Fig. 3). At 16 μg/ml, AvBD-12, AvBD-12A1, AvBD-
12A2 and AvBD-12A3 killed 74.4%, 88.6%, 100%,
100% of E. coli; 47.3%, 95.6%, 93.9%, and 93.9% S.
Typhimurium; 35.5%, 72.3%, 98%, and 100% of P. aer-
uginosa; and 52.9%, 77.2%, 83.1%, and 91.7% of S.
aureus, respectively. AvBD-12A2 and A3 with a net
positive charge of +9 and hydrophobicity of 40% were
more effective than AvBD-12A1 (charge = +5, hydro-
phobicity = 53%). AvBD-12A2 and AvBD-12A3 which
had identical charge and hydrophobicity but altered
locations of alanine/serine residues exhibited different
killing activities against E. coli or P. aeruginosa
(Fig. 3). The bactericidal potency of group-1 ana-
logues can be ranked as AvBD-12A3 > AvBD-12A2 >
AvBD-12A1 > AvBD-12. Of the bacterial species tested,
E. coli and P. aeruginosa were more susceptible than S.
Typhimurium and S. aureus to AvBD-12A3 at medium
concentrations, ranging from 8 μg/ml to 32 μg/ml (Fig. 3).
Group 2 analogues, including AvBD12A4, AvBD-
12A5, and AvBD-12A6 showed similar killing activity to
that of AvBD-12 (Fig. 4). One exception was AvBD-
12A4 was an exception that lost one disulfide bridge
(C1-C5 or C5-C34) was shown to have weaker action
than AvBD-12 against S. Typhimurium (p < 0.05). Group
3 or the hybrid analogue, AvBD-12/6 with the backbone
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of AvBD-12 and positively charged amino acid residues
of AvBD-6 exhibited similar killing activities to that of
AvBD-6 (Fig. 5).
Minimum inhibitory concentration
The MIC-ls of AvBD-12A1, AvBD-12A2 and AvBD-12A3
against E. coli, S. Typhimurium, and P. aeruginosa were 2
to 16-fold below that of AvBD-12, confirming the im-
proved antimicrobial property of these analogues. The
MIC-ls of these analogues against P. aeruginosa were 2 to
8-fold below that of AvBD-6. The ratio of MBC-ls/MIC-ls
was equal to or below 4:1 for AvBD-12A2 and AvBD-
12A3 against the three Gram negative bacterial species
tested, suggesting a bactericidal action [29]. The MIC-ls of
AvBD-12A4, AvBD-12A5, and AvBD-12A6 with 2, 1 and
0 disulfide bridges, respectively, were higher than that of
AvBD-12 and AvBD-6, indicating that removal of disulfide
bridges compromised AvBD’s antimicrobial function.
The MIC-ls of AvBD analogues was negatively correlated
with the net positive charge. The correlation co-efficiencies
(r) for E. coli, S. Typhimurium, P. aeruginosa, and S. aureus
were −0.7388, p < 0.05; −0.8545, p < 0.01; −0.8545, p < 0.01;
and −0.8727, p < 0.01, respectively. Although increasing
hydrophobicity also resulted in improved antimicrobial po-
tency, a positive correlation between hydrophobicity and
antimicrobial activity was not found.
Table 1 Amino acid sequences of avian β-defensin-12 (AvBD-12) analogues
aDisulfide bridges (S-S) between C1–5, C2–4, C3–6
bU: α-aminobutyric acid
cAcidic amino acids, basic amino acids, and cysteines are highlighted in blue, red, and green color, respectively. C1C2C3C4C5C6 or C5 C12 C17 C27 C34 C35
Fig. 1 The predicted three dimensional structures of AvBD-6 and AvBD-12. I-TASSER online service program was used to predict peptide structures.
a Superimposition of the three dimensional structures of AvBD-12 and hBD-6. The CCR2 binding surface of hBD6 is highlighted in purple and the
corresponding region in AvBD-12 is highlighted in yellow. b Superimposition of AvBD-12 and AvBD-6. c Distribution of positively and negatively
charged amino acid residues in AvBD-12. d Distribution of positively charged amino acids in AvBD-6. Basic and acidic amino acids are highlighted in
red and blue, respectively
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Fig. 2 The predicted β2-β3 loop in AvBD-12A2 and AvBD-12A3. a Superimposition of AvBD-12A2 (green) and AvBD-12A3 (red) revealing the structural
differences in the β2-β3 loop, a component of CCR2 binding domain. b Enlarged review of the β2-β3 loop in AvBD-12A2. The hydrogen bond
between the -C = O group of F28 main chain and the -NH group of R29 side chain causes the arginine residue to fold back. c Enlarged
review of the β2-β3 loop in AvBD-12A3. The CHO interactions between S27 -OH groups and the -CH groups on the aromatic ring of F28 result in an
outward protrusion of R29 and a parallel twist of F28 aromatic ring. Distance: Å
Fig. 3 Antimicrobial activity of group 1 analogues. Bacteria (105 CFU/ml) were incubated with peptides at various concentrations, ranging from 2
to 128 μg/ml at 37 °C for 2 h. Antimicrobial activity was presented as percent of killing compared to non-AvBD treated control. Antimicrobial
activity of analogues against E. coli (a), P. aeruginosa (b), S. Typhimurium (c) and S. aureus (d). Data are means ± SD (n = 3). Statistical analysis was
performed using one-way analysis of variance (ANOVA) followed by Duncan’s test for multiple comparisons using software SPSS version 19.0 (IBM
Corp., Armonk, NY). Asterisk indicates statistically significant difference between the analogues and AvBD-12 at the same concentrations (*p < 0.05).
Solid line: average killing percent of 32 μg/ml of wild-type AvBD-12. Dash line: average killing percent of 4 μg/ml of wild-type AvBD-12
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Fig. 4 Antimicrobial activity of group 2 analogues. Bacteria (105 CFU/ml) were incubated with peptides at various concentrations, ranging from 2
to 128 μg/ml, at 37 °C for 2 h. Antimicrobial activity was presented as percent of killing compared to non-AvBD treated control. Antimicrobial activity
of analogues AvBD-12A4 to A6 against E. coli (a), P. aeruginosa (b), S. Typhimurium (c) and S. aureus (d). Wild-type AvBD-6 and AvBD-12 were included
as controls. Data are means ± SD (n = 3). Statistical analysis was performed using the one-way analysis of variance (ANOVA) followed by Duncan’s test
for multiple comparisons using software SPSS version 19.0 (IBM Corp., Armonk, NY). Asterisks indicate statistically significant difference between
analogues and AvBD-12 at the same concentrations (*p < 0.05). Solid line: average killing percent of 32 μg/ml of wild-type AvBD-12. Dash
line: average killing percent of 4 μg/ml of wild-type AvBD-12
Fig. 5 Antimicrobial activity of hybrid peptide AvBD-12/6. Bacteria (105 CFU/ml) were incubated with peptides at various concentrations, ranging
from 2 to 128 μg/ml, at 37 °C for 2 h. Antimicrobial activity was presented as percent of killing compared to non-AvBD treated control. Antimicrobial
activity of analogue AvBD-12/6 against E. coli (a), P. aeruginosa (b), S. Typhimurium (c) and S. aureus (d). Wild-type AvBD-6 and AvBD-12 were included
as controls. Data are means ± SD (n = 3). Statistical analysis was performed using the one-way analysis of variance (ANOVA) followed by Duncan’s test
for multiple comparisons using software SPSS version 19.0 (IBM Corp., Armonk, NY). Asterisks indicate statistically significant difference between the
hybrid analogue and AvBD-12 at the same concentrations (*p < 0.05). Solid line: average killing percent of 32 μg/ml of wild-type AvBD-12. Dash line:
average killing percent of 4 μg/ml of wild-type AvBD-12
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Next, the MICs of AvBD-12A3, the most potent analogue,
and the parent AvBD-6 and AvBD-12 were evaluated under
conditions outlined in CLSI guidelines [27, 28]. High MICs
(128 to 256 μg/ml or above) were obtained (Table 2).
Susceptibility to NaCl
The impact of NaCl on the killing activity of AvBDs was
assessed at NaCl concentrations ranging from 5 to
150 mM. Increasing NaCl concentration had less adverse
impact on the killing activity of AvBD-12A2 and AvBD-
12A3 which had a higher net positive charge (+9) and
hydrophobicity (40%) than AvBD-12 (Fig. 6). AvBD-
12A1, the most hydrophobic (53%) analogue, showed
similar or increased susceptibility to NaCl, compared to
AvBD-12 (Fig. 6). Susceptibility to NaCl was also influ-
enced by the bacterial species under investigation. At
150 mM NaCl, AvBD-12A2 and AvBD-12A3 retained
approximately 80% of killing potency against E. coli and
P. aeruginosa, but only 30% to 60% of killing activity
against S. Typhimurium and S. aureus (Fig. 6). AvBD-
12A4, AvBD-12A5, and AvBD-12A6 with fewer disulfide
bridges were equally or more susceptible to NaCl than
AvBD-12 (Fig. 7). AvBD-12/6 with the backbone of
AvBD-12 and increased net positive charge (+5) resem-
bled AvBD-6 instead of AvBD-12 (Fig. 8).
Cytotoxicity to host cells
Cell cytotoxicity of most potent analogue AvBD-12A3
(+9) and the hybrid analogue AvBD-12/6 (+5) was deter-
mined. Exposure of chicken macrophage cell lines HD11
and MQ-NCSU, murine dendritic cell line JAWSII and
CHO-K1 cells to AvBDs at concentrations of 4, 16, 64,
256 μg/ml for 4, 12, 24, and 48 h did not affect cell vari-
ability. Data on the highest peptide concentration (256 μg/
ml) at various exposure times were presented in
Additional file 1: Figure S1. The results were consistent
with our previous findings that AvBD-6 and AvBD-12 were
non-cytotoxic to avian and mammalian cell lines [26].
Chemotactic activity
Group 1 analogues AvBD-12A1, AvBD-12A2 and
AvBS-12A3 showed minimal chemotactic activity for
CCR2-CHO cells (Fig. 9a). However, AvBD-12A2 and
AvBD-12A3 at 64 μg/ml demonstrated mild (C.I. = 2.37;
35.9% of wild type) and modest (C.I. = 3.74; 56.6% of
wild type) chemotactic activity, respectively, for JAWSII
cells (Fig. 9b). Analogues AvBD-12A4 with two disul-
fide bridges had mild chemotactic activity for CCR2-
CHO (C.I. = 1.48 to 2.18) and JAWSII cells (C.I. =
1.05 to 1.86) which were significantly below the
chemotactic index of parent peptide AvBD-12 (p <
0.01, Fig. 9c and d). AvBD-12A5 with one disulfide
bridge and AvBD-12A6 with zero disulfide bridges
lost their chemotactic activity for both CCR2-CHO-
K1 and JAWSII cells (Fig. 9c and d). The hybrid
AvBD-12/6 retained the chemotactic function of the
backbone peptide AvBD-12 (Fig. 9e and f ).
SEM observation
Mid-logarithmic-phase S. Typhimurium bacteria treated
with AvBD-12A3 (Fig. 10a), AvBD-12/6 (Fig. 10b),
AvBD-12 (Fig. 10c) and AvBD-6 (Fig. 10d) displayed cell
membrane damage (arrow 1) and cell deformation
(arrow 2). Mid-logarithmic-phase S. Typhimurium cells
treated with PBS showed normal size and intact struc-
ture (Fig. 10f, arrow 4). Cell death in stationary-phase
culture (Fig. 10e, arrow 3) showed loss of intracellular
content and uniform membrane structure.
Discussion
Due to the broad spectrum antimicrobial activity, LPS-
neutralizing property, immunomodulatory function and
the low cell cytotoxicity, defensins may serve as natural
antimicrobial peptides or templates for novel drug de-
sign [14, 20, 26, 34, 35]. It has been reported that the
three conserved disulfide bridges are required for the
chemotactic function, but not the antimicrobial activity











Defensins MIC-ls MBC-ls MIC MIC-ls MBC-ls MIC MIC-ls MBC-ls MIC MIC-ls MBC-ls MIC
AvBD-12-A1 8 32 N/A 32 128 N/A 32 256 N/A 256 >256 N/A
AvBD-12-A2 4 16 N/A 16 64 N/A 16 32 N/A 256 256 N/A
AvBD-12-A3 4 16 128 16 64 >256 8 16 >256 128 256 >256
AvBD-12-A4 128 >256 N/A 256 >256 N/A 256 >256 N/A >256 >256 N/A
AvBD-12-A5 64 256 N/A 256 >256 N/A 256 >256 N/A >256 >256 N/A
AvBD-12-A6 64 256 N/A 256 >256 N/A 256 >256 N/A >256 >256 N/A
AvBD-12/6 8 32 256 16 64 >256 64 256 >256 256 256 256
AvBD-6 4 16 128 16 64 >256 64 128 >256 256 256 256
AvBD-12 32 128 256 128 256 >256 128 >256 >256 256 256 >256
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Fig. 6 Effect of NaCl on the antimicrobial activity of group one AvBDs. Bacteria were treated with group one analogues in the presence of 5 mM,
50 mM, 100 mM or 150 mM NaCl. AvBDs were used at the following concentrations: 16 μg/ml against E. coli (a), 32 μg/ml against P. aeruginosa
(b) and S. Typhimurium (c) and 64 μg/ml against S. aureus (d). These concentrations were chosen to ensure more than 50% of killing of inoculum
by majority of analogues. Results are expressed as percent of killing compared to the no-salt control. Data shown are means ± SD (n = 3). Statis-
tical analysis was performed using the one-way analysis of variance (ANOVA) followed by Duncan’s test for multiple comparisons using software
SPSS version 19.0 (IBM Corp., Armonk, NY). Asterisks indicate statistically significant difference among different treatment groups
(*p < 0.05, **p < 0.01)
Fig. 7 Effect of NaCl on the antimicrobial activity of group two analogues. Bacteria were treated with group two analogues in the presence of 5 mM,
50 mM, 100 mM or 150 mM NaCl. AvBDs were used at the following concentrations: 16 μg/ml against E. coli (a), 32 μg/ml against P. aeruginosa (b)
and S. Typhimurium (c) and 64 μg/ml against S. aureus (d). These concentrations were chosen to ensure more than 50% of killing of inoculum by
majority of analogues. Results are expressed as percent of killing compared to the no-salt control. Data shown are means ± SD (n = 3). Statistical ana-
lysis was performed using the one-way analysis of variance (ANOVA) followed by Duncan’s test for multiple comparisons using software SPSS version
19.0 (IBM Corp., Armonk, NY). Asterisks indicate statistically significant difference among different treatment groups (*p < 0.05, **p < 0.01)
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Fig. 8 Effect of NaCl on the antimicrobial activity activity of group three analogue AvBD-12/6. Bacteria were treated with AvBDs in the presence
of 5 mM, 50 mM, 100 mM or 150 mM NaCl. AvBDs were used at the following concentrations: 16 μg/ml against E. coli (a), 32 μg/ml against
P. aeruginosa (b) and S. Typhimurium (c) and 64 μg/ml against S. aureus (d). These concentrations were chosen to ensure more than 50% of killing
of inoculum by majority of analogues. Results are expressed as percent of killing compared to the no-salt control. Data shown are means ± SD
(n = 3). Statistical analysis was performed using the one-way analysis of variance (ANOVA) followed by Duncan’s test for multiple comparisons
using software SPSS version 19.0 (IBM Corp., Armonk, NY). Asterisks indicate statistically significant difference among different treatment groups
(*p < 0.05, **p < 0.01)
Fig. 9 Chemotactic activity of AvBD-12 analogues for CCR2 transfected CHO-K1 cells and mouse immature dendritic JAWSII cells. Migration of
CCR2 transfected CHO-K1 cells (a-c) and mouse immature dendritic JAWSII cells (d-f). The results are expressed as chemotactic index (C.I.): the
number of migrated cells induced by AvBD analogues / the number of migrated cells in response to chemotactic buffer. Data are means ± SD
(n = 5). Statistical analysis was performed using the one-way analysis of variance (ANOVA) followed by Duncan’s test for multiple comparisons
using software SPSS version 19.0 (IBM Corp., Armonk, NY). Asterisks indicate statistically significant difference between analogues and wild-type
AvBD-12 (*p < 0.05, **p < 0.01)
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of mammalian β-defensins [17, 22–25]. However, data
from our previous studies indicate that the correct for-
mation of disulfide bridges via oxidative folding is re-
quired for maximum antimicrobial activity [21, 26]. In
an effort to identify key structural components import-
ant to the antimicrobial and chemotactic activities of
AvBDs, we compared the predicted three dimensional
structures of AvBDs with the well characterized struc-
ture of human beta-defensin 6 (hBD6). It was previously
shown that the N-terminal α-helix and an adjacent β2-
β3 loop form a contiguous binding surface for CCR2
[32]. The presence of a similar CCR2 binding domain in
AvBD-12 may account for the chemotactic activity of
AvBD-12 for both avian and mammalian immune cells
because AvBD-6 which had an N-terminal coil instead
of the α-helix was chemotactic only for avian cells [26].
To further understand the structure-activity relation-
ship, we designed and evaluated seven synthetic ana-
logues of AvBD-12. In the first group of analogues,
disulfide bridges were removed by replacing cysteines
with structurally similar residues (alanine or serine)
whereas peptide hydrophobicity and charge were in-
creased by substituting negatively charged residues with
hydrophobic (AvBD-12A1) or positively charged residues
(AvBD-12A2 and A3). All members of the first group
demonstrated stronger antimicrobial activity than their
parent peptide AvBD-12, indicating that cysteine-free
(linear) AvBDs with a high net positive charge and mod-
erate hydrophobicity can be potent antimicrobial agents.
Such linear peptides can be synthesized without
oxidative folding which simplifies the production process
and reduces cost. In the present study, anti-S.
Typhimurium activity of AvBD-12A1 decreased signifi-
cantly as peptide concentration increased from 64 μg/ml
to 128 μg/ml (Fig. 3c). Similar results were obtained re-
peatedly, suggesting that the decrease was unlikely caused
by technical errors. We hypothesize that AvBD-12A1, the
most hydrophobic (53%) peptide may form aggregates
which interferes with peptide binding to Salmonella mem-
brane components, resulting in a reduction in antimicro-
bial potency. Interestingly, AvBD-12A2 and AvBD-12A3
with identical charge and hydrophobicity, but different
locations of three alanine and three serine residues
(AvBD-12A3: S5S12S17A27A34A35 and AvBD-12A3:
A5A12A17S27S34S35) showed significant difference in
antimicrobial and chemotactic activities. Structural ana-
lysis of AvBD-12A3 revealed an outward protrusion of
R29 side chain and parallel twist F28 aromatic ring. We
hypothesize that the outward protrusion of a positively
charged residue and an adjacent aromatic ring enhances
the interaction between AvBD-12A3 and microbial surface
components or CCR2, thereby facilitating antimicrobial
and chemotactic functions.
To assess the role of disulfide bridges independent of
charge and hydrophobicity, we replaced cysteine residues
with isosteric α-aminobutyric acids (Abu, U) to create
group 2 analogues. Our data indicated that missing even
one conserved disulfide bridge resulted in a significant
reduction in AvBD’s chemotactic activity. Elimination of
two or three disulfide bridges completely abolished the
Fig. 10 Scanning electron microscopy (SEM) of S. Typhimurium treated with AvBDs. Mid-logarithmic-phase S. Typhimurium cells (108 CFU) were
incubated with AvBDs at a final concentration of 1 ×MIC-ls for 30 min. a AvBD-12A3, b AvBD-12/6, c AvBD-12, d AvBD-6, e Stationary phase bacteria,
f Mid-logarithmic-phase S. Typhimurium treated with PBS. Arrow 1, membrane damage. Arrow 2, cell deformation. Arrow 3, cell death in stationary-phase
culture. Arrow 4, a normal cell in mid-logarithmic-phase culture. Scale bar: 5 μm
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chemotactic activity for both avian CCR2-positive cells
and murine immature dendritic cells. It has been shown
that C1 and C4 essential to the formation of first and
second disulfide bridges are located at the CCR2 binding
center [32]. Thus substitution of C with U may have dis-
rupted the CCR2 binding surface, resulting in the loss of
chemotactic activity. Our data also showed that removal
of disulfide bridges had varying degrees of negative im-
pact on AvBD’s antimicrobial activity. Analogue AvBD-
12A4 missing the C1-C5 bridge was nearly inactive
against S. Typhimurium. These results collectively sug-
gest that all three disulfide bridges are needed in the nat-
ural form of AvBDs to maintain tertiary structural
features critical to interacting with microbial surface
components and CCRs on immune cells.
Besides antimicrobial assays, SEM was performed to il-
lustrate the killing mechanisms of AvBD-12 analogues.
Treatment of S. Typhimurium with AvBD-12A3 and
AvBD-12/6, and wild-type AvBD-6 and AvBD-12 caused
similar ultrastructural changes, including cell deform-
ation and membrane damage. Giant cells were only ob-
served among treatment groups, indicating membrane
permeabilization is an essential step in the killing of mi-
crobes by AvBDs.
Salt sensitivity is a major obstacle to the application of
β-defensins as chemotherapeutic agents. Different strat-
egies have been explored to increase the resistance of
beta-defensins to salts, such as N-terminal deletion [36],
combining sequences of HBD-1 and salt-resistant
θ-defensin [37] and replacement of tryptophan or histi-
dine with a bulky amino acid β-naphthylalanine [38]. In
the present study, we found that increasing peptide
charge significantly reduced the impact of NaCl on the
antimicrobial efficacy of AvBD-12A2 and AvBD-12A3.
However, the activity against S. Typhimurium was still
severely inhibited by physiological concentration of NaCl
(150 mM), suggesting that different mechanisms are in-
volved in killing different bacterial species.
In the present study, we also determined the minimum
inhibitory concentrations (MICs) of AvBDs. Using the
standard Muller Hinton II broth, the MICs of the parent
AvBDs and the most potent analogue AvBD-12A3 were
much higher than the MIC values obtained under the
low-salt and low-nutrient condition. We hypothesize
that interference of initial peptide-bacteria interactions
by cationic salts as well as enzymatic degradation or
modification of AvBDs during bacterial growth in a nu-
trient rich Mueller-Hinton broth might have contributed
to the decreased antimicrobial activity. It has been
shown that human cathelicidin LL-37 could be hydro-
lyzed by S. aureus protease or cleaved by metallopro-
tease, gelatinase or cysteine protease produced by other
bacterial species [39]. Proteolytic degradation is one of
the main mechanisms that both gram-positive and
gram-negative bacteria use to evade host antimicrobial
peptide killing [40–45]. Further modification is clearly
needed to improve the efficacy of AvBD-12A3 as an
antimicrobial agent. It is noteworthy that all AvBD
analogues remain non-cytotoxic to avian and mamma-
lian cells.
Conclusions
The three conserved disulfide bridges maintaining the
tertiary structure of natural AvBDs are required not only
for the chemotactic activity, but also for maximum anti-
microbial activity. AvBD-12A3 with increased net posi-
tive charge and a CCR2-binding domains (N-terminal α-
helix and β2-β3 loop) demonstrated potent antimicrobial
activity and retained partial chemotactic property.
Analogue AvBD-12A3 may serve as a template for the
design of novel antimicrobial peptides as therapeutic
agents for both avian and mammalian hosts.
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means ± SD (n = 3). Student t-test was performed to analyze differences
between AvBD-treated and untreated cells. No significant difference was
found. (TIFF 391 kb)
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